This clinical quandary discusses oligoprogressive disease in metastatic melanoma and how treatment with immunotherapy and targeted therapy affect the disease.
Miguel A. Álvarez-Avitia, MD
Advertisement
Articles by Miguel A. Álvarez-Avitia, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
Novel HP1K Inhibitor Shows Favorable Responses in ccRCC, Solid Tumors
3
FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
4
119 Progression-Free Survival (PFS) and Overall Survival (OS) Results From the Phase 3 MONALEESA-3 Trial of Postmenopausal Patients With Hormone Receptor–Positive (HR+)/Human Epidermal Growth Factor Receptor 2–Negative (HER2−) Advanced Breast Cancer (ABC) Treated With Ribociclib (RIB) + Fulvestrant (FUL): A Subgroup Analysis of Patients With Invasive Lobular Carcinoma (ILC)
5